B-type Natriuretic Peptide CLIA Kit


Product Name: B-type Natriuretic Peptide CLIA Kit (Chemiluminescence Immunoassay) Abbreviation: BNP 


B-type Natriuretic Peptide CLIA Kit (Chemiluminescence Immunoassay) is an in vitro diagnostic test for the quantitative detection of B-type natriuretic peptide (BNP) in human plasma specimen. This product is intended to be used by laboratory professional workers only. This kit is used for auxiliary diagnosis. Results must be combined with clinical observations, patient history, other laboratory parameters, and epidemiological information for comprehensive analysis. BNP has the effect of antagonizing RASS and SNS and can inhibit the synthesis of vasoconstrictor substances such as catecholamine, angiotensin I, aldosterone and endothelin-1. Experiments have confirmed that BNP can increase sodium excretion by more than 2 times and reduce aldosterone secretion by 50%. By acting on the hypothalamus, BNP changes the regulation of angiotensin and vasopressin on the hypothalamus, indirectly causing changes in blood pressure, and can also affect renal nerve activity, causing changes in renin secretion, thereby indirectly causing changes in blood pressure. Application of BNP in patients with congestive heart failure can reduce peripheral vascular resistance, right atrial pressure, and increase ejection fraction (EF). Application of BNP in normal people can reduce vascular resistance, while EF remains unchanged. BNP dilates afferent arterioles, constricts efferent arterioles, increases glomerular capillary internal pressure, thereby increasing glomerular filtration rate, reducing collecting duct sodium reabsorption and transport, increasing sodium excretion, and inhibiting RASS system, leading to natriuretic and diuretic effects. The relationship between BNP and hemodynamic changes has been widely recognized. The plasma concentration of BNP is closely related to the state of cardiac function. Normal BNP concentration can largely deny the existence of impaired cardiac function. Many studies have shown that BNP can be used to diagnose LVD caused by various diseases. However, due to the different conditions of different laboratories, the detection methods and research methods adopted are not the same, and the obtained normal values are all different, which needs to be studied and improved further. And it should be noted that BNP is not a specific diagnostic tool, because elevated plasma BNP concentration is not necessarily caused by heart failure, some cardiopulmonary diseases, renal failure, liver cirrhosis, etc. can also increase plasma BNP concentration, and it should be combined with clinical data to identify